Evidence map›Paper›PMID 39811764›Full record

ArticlePatient preference and adherence2025

Experiences of Oral Corticosteroid Use and Adverse Effects: A National Cross-Sectional Survey of People with Asthma.

Arwel W Jones, Vanessa M McDonald, Rebecca F McLoughlin, Teresa M Vella, Anthony W Flynn, John D Blakey, Luke Wolfenden, Mark Hew, John W Upham, Dennis Thomas and 2 more

Abstract read
In one paragraph

Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Arwel W JonesRespiratory Research@Alfred, Monash University, Melbourne, VIC, Australia.ORCID 0000-0003-1689-8065
Vanessa M McDonaldCentre of Excellence in Treatable Traits, University of Newcastle, Newcastle, NSW, Australia.ORCID 0000-0001-9890-3408
Rebecca F McLoughlinCentre of Excellence in Treatable Traits, University of Newcastle, Newcastle, NSW, Australia.ORCID 0000-0002-9874-4862
Teresa M VellaBrand and Engagement, Asthma Australia, Brisbane, QLD, Australia.
Anthony W FlynnResearch, Information and Evaluation, Asthma Australia, Melbourne, VIC, Australia.
John D BlakeyRespiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Luke WolfendenHunter New England Population Health, Wallsend, NSW, Australia.
Mark HewAllergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, VIC, Australia.
John W UphamFrazer Institute, University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0002-0017-3433
Dennis ThomasCentre of Excellence in Treatable Traits, University of Newcastle, Newcastle, NSW, Australia.
Philip BardinMonash Lung Sleep Allergy & Immunology, Monash University and Medical Centre, Clayton, VIC, Australia.
Anne E HollandRespiratory Research@Alfred, Monash University, Melbourne, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Oral corticosteroids (OCS) are an effective treatment for severe uncontrolled asthma or asthma exacerbations, but frequent bursts or long-term use carry serious and sometimes irreversible adverse effects, or complications such as adrenal insufficiency upon discontinuation. Our aim was to survey people with asthma on their experiences of, and attitudes towards, using OCS. Patients and Methods: This study was a national descriptive cross-sectional survey of people with asthma in Australia. An anonymous survey was hosted online with invitations to participate distributed by national consumer peak bodies. Survey free-text responses were coded to the Theoretical Domains Framework (TDF) to elicit determinants of OCS use. Results: 1808 people with asthma participated between 3 and 16 May 2022. Most common reasons for using OCS were severe asthma symptoms (40%), doctor prescription (38%) or asthma action plan recommendations (20%). Approximately 55% of people had experienced adverse effects from OCS use. Commonly reported adverse effects were trouble sleeping (69%), weight gain (56%) and mood problems (41%). Of people who had OCS at home or an OCS script, 44% did not have an action plan that described when and how they should take them. People (33%) did not feel well informed about OCS adverse effects from their healthcare team. People had varied awareness (3-65%) of current available strategies to reduce OCS use. 'Knowledge', 'Environmental context and resources' and 'Social influences' were the most coded TDF domains influencing OCS use. Conclusion: Adverse effects of OCS use are common. People with asthma are not adequately informed about optimal OCS use or strategies to reduce overuse. These findings can help guide the implementation of OCS stewardship initiatives.

Indexed as

asthmaattitudeconsumer behaviourcorticosteroidspatient participation

Identifiers

PMID39811764
PMCPMC11730280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.